ticlopidine has been researched along with Graft Occlusion, Vascular in 168 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Graft Occlusion, Vascular: Obstruction of flow in biological or prosthetic vascular grafts.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In CHAMPION PHOENIX, cangrelor reduced ischaemic events with no significant increase in GUSTO-defined severe bleeding." | 9.22 | The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. ( Bhatt, DL; Blankenship, JC; Deliargyris, EN; Généreux, P; Gibson, CM; Gutierrez, JA; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016) |
| "Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding." | 9.22 | Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD, 2016) |
| "The aim of this study was to assess the relationship between sex and clinical outcomes and treatment-related complications in patients with ST-elevation or non-ST-elevation acute coronary syndromes (ACS) randomized to treatment with ticagrelor or clopidogrel in the PLATelet inhibition and patient Outcomes (PLATO) trial." | 9.19 | The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bach, RG; Becker, RC; Budaj, A; Heras, M; Himmelmann, A; Horrow, J; Husted, S; James, SK; Katus, HA; Lassila, R; Morais, J; Nicolau, JC; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D, 2014) |
| "The benefit of extending clopidogrel treatment beyond the 12-month period recommended in current guidelines after myocardial infarction (MI) is debated." | 7.78 | Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study. ( Ahlehoff, O; Charlot, M; Gislason, GH; Hansen, ML; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Nielsen, LH; Olsen, AM; Torp-Pedersen, C, 2012) |
| "AIMS Immediate treatment with a loading dose of clopidogrel at diagnosis of ST-segment elevation myocardial infarction (STEMI) is recommended by ESC/AHA/ACC guidelines in patients eligible for primary percutaneous coronary intervention (PCI)." | 7.77 | Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Scherstén, F; Smith, JG, 2011) |
| "The incidence of thrombocytopenia with ticlopidine and clopidogrel when used in conjunction with abciximab has not been systematically addressed." | 7.70 | Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine. ( Dillon, JC; Dillon, WC; Eckert, GJ; Ritchie, ME, 2000) |
| "Aspirin has been convincingly shown to reduce stroke and death in men with transient ischemic attacks (it may possibly be beneficial to women also), myocardial infarction and death in patients with unstable angina, thromboembolic complications associated with artificial heart valves in patients receiving oral anticoagulants (although gastrointestinal bleeding is prohibitive with this combination), and thrombotic occlusion of silicone rubber arteriovenous cannulae in uremic patients undergoing hemodialysis." | 6.15 | Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis. ( Harker, LA, 1986) |
| "In CHAMPION PHOENIX, cangrelor reduced ischaemic events with no significant increase in GUSTO-defined severe bleeding." | 5.22 | The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. ( Bhatt, DL; Blankenship, JC; Deliargyris, EN; Généreux, P; Gibson, CM; Gutierrez, JA; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016) |
| "Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding." | 5.22 | Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD, 2016) |
| "The aim of this study was to assess the relationship between sex and clinical outcomes and treatment-related complications in patients with ST-elevation or non-ST-elevation acute coronary syndromes (ACS) randomized to treatment with ticagrelor or clopidogrel in the PLATelet inhibition and patient Outcomes (PLATO) trial." | 5.19 | The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bach, RG; Becker, RC; Budaj, A; Heras, M; Himmelmann, A; Horrow, J; Husted, S; James, SK; Katus, HA; Lassila, R; Morais, J; Nicolau, JC; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D, 2014) |
| "The purpose of this pre-specified analysis of the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) was to assess device-specific outcomes relative to different duration of dual antiplatelet therapy (DAPT) after Everolimus- (EES), Paclitaxel (PES), Zotarolimus- (ZES-S) eluting, or bare metal stents (BMS)." | 5.17 | Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). ( Borghesi, M; Ferrari, R; Parrinello, G; Tebaldi, M; Valgimigli, M; Vranckx, P, 2013) |
| "Clopidogrel reduces the frequency of early thrombosis of new arteriovenous fistulas but does not increase the proportion of fistulas that become suitable for dialysis." | 5.13 | Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. ( Allon, M; Beck, GJ; Braden, GL; Davidson, IJ; Delmez, JA; Dember, LM; Dixon, BS; Feldman, HI; Gassman, JJ; Greenberg, A; Greene, T; Himmelfarb, J; Ikizler, TA; Kaufman, JS; Kusek, JW; Meyers, CM; Radeva, MK; Rocco, MV; Vazquez, MA, 2008) |
| "The association between DAPT interruption and the rates of stent thrombosis (ST) and cardiac death/target-vessel myocardial infarction (CD/TVMI) in patients receiving a Resolute zotarolimus-eluting stent (R-ZES) was analysed in 4896 patients from the pooled RESOLUTE clinical programme." | 4.90 | Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation. ( Belardi, JA; Brar, S; Kirtane, AJ; Liu, M; Rothman, M; Silber, S; Windecker, S, 2014) |
| "Despite well-documented efficacy, recurrent thrombotic event occurrences, particularly stent thrombosis, have been repeatedly demonstrated in stented patients treated with aspirin and clopidogrel." | 4.90 | Resistance to antiplatelet drugs: what progress has been made? ( Bliden, KP; Gesheff, M; Gurbel, PA; Liu, F; Tantry, US, 2014) |
| "The optimal length of clopidogrel therapy in patients with acute coronary syndromes or in those who have undergone percutaneous coronary intervention (PCI) remains controversial." | 4.87 | Systematic review of thienopyridine discontinuation and its impact upon clinical outcomes. ( Gaglia, MA; Waksman, R, 2011) |
| " Monotherapy with either aspirin or clopidogrel, reduces the rate of stroke, myocardial infarction, and cardiovascular death in patients suffering from peripheral arterial disease." | 4.85 | Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy? ( Milani, RV, 2009) |
| " The aim of the study was to verify whether clopidogrel response measured by Multiplate analyzer (ADPtest) in diabetic ACS patients treated with PCI predicts the risk of stent thrombosis or cardiovascular mortality and bleeding." | 3.83 | Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome. ( Bekta, P; Chmielak, Z; Debski, A; Jamiolkowski, J; Klopotowski, M; Kukula, K; Kunicki, PK; Polanska-Skrzypczyk, M; Witkowski, A, 2016) |
| " No data exist about the impact of HRPR after 600 mg clopidogrel loading on long-term clinical outcome in patients with diabetes mellitus and treated with percutaneous coronary angioplasty (PCI) for chronic total occlusion (CTO)." | 3.81 | Prognostic impact of high residual platelet reactivity after chronic total occlusion percutaneous coronary intervention in patients with diabetes mellitus. ( Abbate, R; Antoniucci, D; Cantini, G; Carrabba, N; Cerisano, G; Comito, V; Gensini, GF; Gori, AM; Marcucci, R; Marrani, M; Migliorini, A; Parodi, G; Valenti, R; Vergara, R, 2015) |
| "The benefit of extending clopidogrel treatment beyond the 12-month period recommended in current guidelines after myocardial infarction (MI) is debated." | 3.78 | Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study. ( Ahlehoff, O; Charlot, M; Gislason, GH; Hansen, ML; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Nielsen, LH; Olsen, AM; Torp-Pedersen, C, 2012) |
| "The pharmacodynamic analysis end point was clopidogrel on-treatment platelet reactivity (OPR) and the clinical analysis end point was the composite of cardiac death, non-fatal myocardial infarction, ischaemic stroke and stent thrombosis at 12 months post-PCI." | 3.78 | Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention. ( Kang, HJ; Kang, J; Kim, HS; Koo, BK; Lee, HY; Oh, BH; Park, JJ; Park, KW; Park, YB; Yang, HM, 2012) |
| "AIMS Immediate treatment with a loading dose of clopidogrel at diagnosis of ST-segment elevation myocardial infarction (STEMI) is recommended by ESC/AHA/ACC guidelines in patients eligible for primary percutaneous coronary intervention (PCI)." | 3.77 | Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Scherstén, F; Smith, JG, 2011) |
| "The case is reported of a patient presenting with recurrent acute myocardial infarction due to stent thrombosis resulting from possible clopidogrel resistance caused by interaction between clopidogrel and anti-tuberculosis drugs." | 3.74 | Drug interaction with anti-mycobacterial treatment as a cause of clopidogrel resistance. ( Smith, D; Srinivasan, M, 2008) |
| "The incidence of thrombocytopenia with ticlopidine and clopidogrel when used in conjunction with abciximab has not been systematically addressed." | 3.70 | Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine. ( Dillon, JC; Dillon, WC; Eckert, GJ; Ritchie, ME, 2000) |
| "The efficacy of a postoperative treatment with Low molecular weight heparin (LMWH) vs Ticlopidine in controlling early thrombosis, intimal hyperplasia and growth of true endothelial cells in small prosthetic expanded polytetrafluoroethylene (ePTFE) grafts (4 mm) interposed in the carotid artery of sheep has been evaluated." | 3.69 | Pharmacological control of intimal hyperplasia in small diameter polytetrafluoroethylene grafts. An experimental study. ( Baccini, P; Bachi, V; Ceppa, P; Civalleri, D; Decian, F; Desalvo, P; Galleano, R; Lenti, E; Simoni, G, 1996) |
| "Aspirin was to be given indefinitely, and clopidogrel/ticlopidine for ≥ 3 months or up to 12 months after implantation." | 2.79 | Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type. ( Al Kurdi, M; Boersma, E; Camenzind, E; Mauri, L; Ordoubadi, FF; Rademaker-Havinga, T; Steg, PG; Suttorp, MJ; Wijns, W, 2014) |
| "Reactive thrombocytosis has been reported in 20% of patients after coronary artery bypass grafting (CABG), a frequency that might be related to the high incidence of thrombotic complications." | 2.73 | The role of clopidogrel and acetylsalicylic acid in the prevention of early-phase graft occlusion due to reactive thrombocytosis after coronary artery bypass operation. ( Alper, AT; Ates, M; Demirtas, MM; Gunay, R; Idiz, M; Kayacioglu, I; Saskin, H; Sensoz, Y; Tangurek, B; Yekeler, I, 2008) |
| "Aspirin resistance was defined as ARU > 550, whereas clopidogrel resistance was defined as percentage platelet inhibition < 40%." | 2.73 | Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. ( Flaherty, CA; Lee, VH; Lopes, DK; Prabhakaran, S; Wells, KR, 2008) |
| "People with end-stage renal disease (ESRD) often require either the formation of an arteriovenous fistula (AVF) or an interposition prosthetic arteriovenous graft (AVG) for haemodialysis." | 2.72 | Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. ( Da Silva, A; Kamarizan, MFA; Mohamed, I, 2021) |
| "Probucol is a lipid-lowering drug that has an antioxidant effect." | 2.70 | Effect of antioxidant probucol for preventing stent restenosis. ( Cha, KS; Han, JY; Kim, HJ; Kim, JS; Kim, MH, 2002) |
| " No in-hospital adverse cardiac events occurred." | 2.69 | beta-Particle-emitting radioactive stent implantation. A safety and feasibility study. ( Coen, VL; den Boer, A; Gijzel, AL; Kay, IP; Levendag, PC; Ligthart, JM; Sabaté, M; Serruys, PW; van Der Giessen, WJ; Wardeh, AJ, 1999) |
| " Side-effects of ticlopidine were rare and patient management with the standard dosage of this drug was easier than oral anticoagulation." | 2.66 | Platelet inhibitors versus anticoagulants for prevention of aorto-coronary bypass graft occlusion. ( Goebel, N; Krayenbühl, HP; Pfluger, N; Rothlin, ME; Senning, A; Speiser, K; Steinbrunn, W; Turina, M, 1985) |
| "Ticlopidine is an effective inhibitor of platelet aggregation." | 2.66 | Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis. ( Gröntoft, KC; Gutierrez, A; Mulec, H; Olander, R, 1985) |
| "Acute coronary syndrome was the indication for index-PCI in 74% of the patients." | 1.46 | High risk of stent thrombosis in the first 6 months after coronary stenting: Do not discontinue clopidogrel early after ACS. ( Godschalk, TC; Kelder, JC; Ten Berg, JM; Zwart, B, 2017) |
| "Aspirin effect was assessed using the VerifyNow Aspirin Assay, and the effect of clopidogrel was assessed using the VerifyNow P2Y12 Assay and vasodilator-stimulated phosphoprotein phosphorylation (VASP-P)." | 1.35 | Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. ( Beauzile, P; Bonello, L; Gavini, R; Gurbel, P; Kaneshige, K; Kent, K; Pichard, AD; Pinto Slottow, TL; Satler, LF; Scheinowitz, M; Suddath, WO; Sushinsky, SJ; Tantry, U; Torguson, R; Waksman, R; Xue, Z, 2009) |
| "Intimal hyperplasia is a major cause of restenosis after the interventional or surgical treatment of occlusive arterial disease." | 1.35 | Reduced intimal hyperplasia in rabbits via medical therapy after carotid venous bypass. ( Bahcivan, M; Erenler, BH; Gol, MK; Keceligil, HT; Kolbakir, F; Yucel, S, 2009) |
| " We present several illustrative cases in which platelet monitoring with the Rapid Platelet Function Assay (RPFA, Accumetrics) was used to guide dosing of a glycoprotein (GP) IIb/IIIa inhibitor for coronary and peripheral intervention among patients at increased bleeding risk." | 1.31 | Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk. ( Chew, DP; Moliterno, DJ; Mukherjee, D; Raymond, RE; Robbins, M; Yadav, JS, 2001) |
| "to investigate the effect of clopidogrel combined with aspirin or aspirin alone on fibromyointimal hyperplasia (FIMH) in a bypass model with native vein grafts (NVG) and biocompound grafts (BCG)." | 1.31 | Prevention of venous graft sclerosis with clopidogrel and aspirin combined with a mesh tubing in a dog model of arteriovenous bypass grafting. ( Gutersohn, A; Hetzer, R; Mülling, C; Musci, M; Sänger, S; Schaffner, T; Wellnhofer, E; Zurbrügg, HR, 2001) |
| "The composition of the thrombus is analyzed by double isotope labeling of platelets and fibrinogen." | 1.28 | [Arterioarterial shunt coated with collagen. A model of acute arterial thrombosis for testing antithrombotic agents in rats]. ( Cazenave, JP; Freund, M; Mantz, F, 1991) |
| "The dry weight of thrombus in the graft in group B and group D was 39 +/- 3 mg and 30 +/- 2 mg, respectively on day 28." | 1.28 | The pathogenesis of thrombosis in venous prostheses. ( Itoh, T; Kambayashi, J; Kawasaki, T; Mori, T; Sakon, M; Shiba, E; Watase, M, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (6.55) | 18.7374 |
| 1990's | 22 (13.10) | 18.2507 |
| 2000's | 66 (39.29) | 29.6817 |
| 2010's | 68 (40.48) | 24.3611 |
| 2020's | 1 (0.60) | 2.80 |
| Authors | Studies |
|---|---|
| Mohamed, I | 1 |
| Kamarizan, MFA | 1 |
| Da Silva, A | 1 |
| Sukul, D | 1 |
| Seth, M | 1 |
| Dixon, SR | 1 |
| Khandelwal, A | 1 |
| LaLonde, TA | 1 |
| Gurm, HS | 1 |
| Li, R | 1 |
| Lan, B | 1 |
| Zhu, T | 1 |
| Yang, Y | 1 |
| Cai, M | 1 |
| Fang, Z | 1 |
| Ma, C | 1 |
| Chen, S | 1 |
| Redfors, B | 1 |
| Ben-Yehuda, O | 1 |
| Lin, SH | 1 |
| Furer, A | 1 |
| Kirtane, AJ | 2 |
| Witzenbichler, B | 1 |
| Weisz, G | 1 |
| Stuckey, TD | 1 |
| Maehara, A | 1 |
| Généreux, P | 3 |
| Giustino, G | 1 |
| Rinaldi, MJ | 1 |
| Neumann, FJ | 5 |
| Metzger, DC | 1 |
| Henry, TD | 1 |
| Cox, DA | 1 |
| Duffy, PL | 1 |
| Mazzaferri, EL | 1 |
| Ayele, GM | 1 |
| Mehran, R | 1 |
| Mintz, GS | 1 |
| Stone, GW | 4 |
| Zwart, B | 2 |
| Godschalk, TC | 1 |
| Kelder, JC | 2 |
| Ten Berg, JM | 4 |
| Tong, MS | 1 |
| Sung, PH | 1 |
| Liu, CF | 1 |
| Chen, KH | 1 |
| Chung, SY | 1 |
| Chua, S | 1 |
| Chen, CJ | 1 |
| Lee, WC | 1 |
| Chai, HT | 1 |
| Yip, HK | 1 |
| Chang, HW | 1 |
| Deo, SV | 1 |
| Dunlay, SM | 1 |
| Shah, IK | 1 |
| Altarabsheh, SE | 1 |
| Erwin, PJ | 1 |
| Boilson, BA | 1 |
| Park, SJ | 2 |
| Joyce, LD | 1 |
| Jerzewski, K | 1 |
| Ruel, M | 2 |
| Voisine, P | 2 |
| Le May, MR | 1 |
| Kulik, A | 2 |
| Pennacchi, M | 1 |
| Stio, RE | 1 |
| Lucisano, L | 1 |
| Calcagno, S | 1 |
| Mancone, M | 1 |
| Sardella, G | 1 |
| Une, D | 1 |
| Le May, M | 1 |
| Ebrahimi, R | 1 |
| Bakaeen, FG | 1 |
| Uberoi, A | 1 |
| Ardehali, A | 1 |
| Baltz, JH | 1 |
| Hattler, B | 1 |
| Almassi, GH | 1 |
| Wagner, TH | 1 |
| Collins, JF | 1 |
| Grover, FL | 1 |
| Shroyer, AL | 1 |
| Silber, S | 1 |
| Belardi, JA | 1 |
| Liu, M | 2 |
| Brar, S | 1 |
| Rothman, M | 1 |
| Windecker, S | 2 |
| Camenzind, E | 1 |
| Boersma, E | 1 |
| Wijns, W | 1 |
| Mauri, L | 1 |
| Rademaker-Havinga, T | 1 |
| Ordoubadi, FF | 1 |
| Suttorp, MJ | 1 |
| Al Kurdi, M | 1 |
| Steg, PG | 4 |
| Husted, S | 2 |
| James, SK | 2 |
| Bach, RG | 1 |
| Becker, RC | 2 |
| Budaj, A | 1 |
| Heras, M | 1 |
| Himmelmann, A | 2 |
| Horrow, J | 1 |
| Katus, HA | 2 |
| Lassila, R | 1 |
| Morais, J | 1 |
| Nicolau, JC | 1 |
| Storey, RF | 2 |
| Wojdyla, D | 1 |
| Wallentin, L | 2 |
| Loh, JP | 1 |
| Torguson, R | 4 |
| Pendyala, LK | 1 |
| Omar, A | 1 |
| Chen, F | 1 |
| Satler, LF | 5 |
| Pichard, AD | 5 |
| Waksman, R | 6 |
| Guo, B | 1 |
| Tan, Q | 1 |
| Guo, D | 1 |
| Shi, Z | 1 |
| Zhang, C | 1 |
| Guo, W | 1 |
| Kakisis, JD | 1 |
| Vassilas, K | 1 |
| Antonopoulos, C | 1 |
| Sfyroeras, G | 1 |
| Moulakakis, K | 1 |
| Liapis, CD | 1 |
| Parekh, P | 1 |
| Agrawal, N | 1 |
| Vasavada, A | 1 |
| Vinchurkar, M | 1 |
| Hajj-Chahine, J | 1 |
| Fu, Z | 1 |
| Dong, W | 1 |
| Shen, M | 1 |
| Xue, H | 1 |
| Guo, J | 1 |
| Jing, J | 1 |
| Han, Y | 2 |
| Yang, X | 1 |
| Chen, Y | 1 |
| Hess, CN | 1 |
| Lopes, RD | 2 |
| Gibson, CM | 2 |
| Hager, R | 1 |
| Wojdyla, DM | 1 |
| Englum, BR | 1 |
| Mack, MJ | 1 |
| Califf, RM | 1 |
| Kouchoukos, NT | 1 |
| Peterson, ED | 1 |
| Alexander, JH | 1 |
| Tantry, US | 2 |
| Gesheff, M | 1 |
| Liu, F | 1 |
| Bliden, KP | 1 |
| Gurbel, PA | 2 |
| Timmers, L | 1 |
| Stella, PR | 1 |
| Agostoni, P | 1 |
| Christ, G | 1 |
| Siller-Matula, JM | 2 |
| Francesconi, M | 1 |
| Dechant, C | 1 |
| Grohs, K | 1 |
| Podczeck-Schweighofer, A | 1 |
| Ferraris, VA | 1 |
| Bolanos, MD | 1 |
| Schulz-Schüpke, S | 1 |
| Byrne, RA | 3 |
| Adriaenssens, T | 1 |
| Tölg, R | 1 |
| Seyfarth, M | 1 |
| Maeng, M | 1 |
| Zrenner, B | 1 |
| Jacobshagen, C | 1 |
| Mudra, H | 2 |
| von Hodenberg, E | 1 |
| Wöhrle, J | 1 |
| Angiolillo, DJ | 4 |
| von Merzljak, B | 1 |
| Rifatov, N | 1 |
| Kufner, S | 1 |
| Morath, T | 2 |
| Feuchtenberger, A | 1 |
| Ibrahim, T | 1 |
| Janssen, PW | 1 |
| Valina, C | 1 |
| Li, Y | 1 |
| Desmet, W | 1 |
| Abdel-Wahab, M | 1 |
| Tiroch, K | 1 |
| Hengstenberg, C | 1 |
| Bernlochner, I | 2 |
| Fischer, M | 1 |
| Schunkert, H | 1 |
| Laugwitz, KL | 1 |
| Schömig, A | 5 |
| Mehilli, J | 5 |
| Kastrati, A | 6 |
| Jim, MH | 1 |
| Wong, KL | 1 |
| Yiu, KH | 1 |
| Sueta, D | 1 |
| Hokimoto, S | 1 |
| Enomoto, K | 1 |
| Ono, T | 1 |
| Tabata, T | 1 |
| Kajiwara, I | 1 |
| Kaikita, K | 1 |
| Saruwatari, J | 1 |
| Oniki, K | 1 |
| Nakagawa, K | 1 |
| Ogawa, H | 1 |
| Aradi, D | 1 |
| Kirtane, A | 1 |
| Bonello, L | 4 |
| Huber, K | 3 |
| Freynhofer, MK | 1 |
| ten Berg, J | 1 |
| Janssen, P | 1 |
| Marcucci, R | 4 |
| Patti, G | 1 |
| Mangiacapra, F | 1 |
| Valgimigli, M | 4 |
| Morel, O | 1 |
| Palmerini, T | 3 |
| Price, MJ | 3 |
| Cuisset, T | 1 |
| Sibbing, D | 3 |
| Liu, C | 1 |
| Chen, D | 1 |
| Liu, H | 1 |
| Jiang, Q | 1 |
| Lu, J | 2 |
| Zuo, L | 1 |
| Valenti, R | 2 |
| Cantini, G | 1 |
| Marrani, M | 1 |
| Migliorini, A | 2 |
| Carrabba, N | 1 |
| Comito, V | 1 |
| Vergara, R | 2 |
| Cerisano, G | 1 |
| Parodi, G | 1 |
| Abbate, R | 3 |
| Gori, AM | 3 |
| Gensini, GF | 3 |
| Antoniucci, D | 3 |
| Gutierrez, JA | 1 |
| Harrington, RA | 2 |
| Blankenship, JC | 1 |
| Hamm, CW | 1 |
| Prats, J | 1 |
| Deliargyris, EN | 1 |
| Mahaffey, KW | 1 |
| White, HD | 1 |
| Bhatt, DL | 2 |
| Briasoulis, A | 1 |
| Palla, M | 1 |
| Kagawa, Y | 1 |
| Shiode, N | 1 |
| Kawase, T | 1 |
| Tamekiyo, H | 1 |
| Okimoto, T | 1 |
| Hayashi, Y | 1 |
| Gargiulo, G | 1 |
| Costa, F | 1 |
| Ariotti, S | 1 |
| Biscaglia, S | 1 |
| Campo, G | 1 |
| Esposito, G | 1 |
| Leonardi, S | 1 |
| Vranckx, P | 2 |
| Shimada, YJ | 1 |
| Bansilal, S | 1 |
| Wiviott, SD | 1 |
| Neely, B | 1 |
| Cannon, CP | 3 |
| Díaz-Villamarín, X | 1 |
| Dávila-Fajardo, CL | 1 |
| Martínez-González, LJ | 1 |
| Carmona-Sáez, P | 1 |
| Sánchez-Ramos, J | 1 |
| Álvarez Cubero, MJ | 1 |
| Salmerón-Febres, LM | 1 |
| Cabeza Barrera, J | 1 |
| Fernández-Quesada, F | 1 |
| Camaro, C | 1 |
| Damen, SA | 1 |
| Brouwer, MA | 1 |
| Kedhi, E | 1 |
| Lee, SW | 3 |
| Verdoia, M | 1 |
| Barbieri, L | 1 |
| Rognoni, A | 1 |
| van T Hof, AW | 1 |
| Ligtenberg, E | 1 |
| de Boer, MJ | 1 |
| Suryapranata, H | 1 |
| De Luca, G | 1 |
| Zhang, JJ | 1 |
| Gao, XF | 1 |
| Ge, Z | 1 |
| Tian, NL | 1 |
| Liu, ZZ | 1 |
| Lin, S | 1 |
| Ye, F | 1 |
| Chen, SL | 1 |
| Kukula, K | 1 |
| Klopotowski, M | 1 |
| Kunicki, PK | 1 |
| Jamiolkowski, J | 1 |
| Debski, A | 1 |
| Bekta, P | 1 |
| Polanska-Skrzypczyk, M | 1 |
| Chmielak, Z | 1 |
| Witkowski, A | 1 |
| Della Riva, D | 1 |
| Benedetto, U | 1 |
| Bacchi Reggiani, L | 1 |
| Feres, F | 1 |
| Abizaid, A | 1 |
| Gilard, M | 1 |
| Morice, MC | 1 |
| Hong, MK | 2 |
| Kim, BK | 1 |
| Jang, Y | 2 |
| Kim, HS | 3 |
| Park, KW | 2 |
| Colombo, A | 1 |
| Chieffo, A | 1 |
| Sangiorgi, D | 1 |
| Biondi-Zoccai, G | 1 |
| Angelini, GD | 1 |
| Pufulete, M | 1 |
| White, J | 1 |
| Kayacioglu, I | 1 |
| Gunay, R | 1 |
| Saskin, H | 1 |
| Idiz, M | 1 |
| Sensoz, Y | 1 |
| Ates, M | 1 |
| Tangurek, B | 1 |
| Alper, AT | 1 |
| Demirtas, MM | 1 |
| Yekeler, I | 1 |
| Moschi, G | 1 |
| Paniccia, R | 2 |
| Buonamici, P | 2 |
| Trenk, D | 1 |
| Hentschel, DM | 1 |
| Asif, A | 1 |
| Wusirika, R | 1 |
| Rao, P | 1 |
| Fourtounas, C | 1 |
| Vlachojannis, JG | 1 |
| Camoin-Jau, L | 1 |
| Armero, S | 1 |
| Com, O | 1 |
| Arques, S | 1 |
| Burignat-Bonello, C | 1 |
| Giacomoni, MP | 1 |
| Bonello, R | 1 |
| Collet, F | 1 |
| Rossi, P | 1 |
| Barragan, P | 2 |
| Dignat-George, F | 1 |
| Paganelli, F | 1 |
| Stegherr, J | 1 |
| Latz, W | 1 |
| Koch, W | 2 |
| Dörrler, K | 1 |
| von Beckerath, N | 1 |
| Milani, RV | 1 |
| Roy, P | 1 |
| Okabe, T | 1 |
| Pinto Slottow, TL | 2 |
| Steinberg, DH | 1 |
| Kaneshige, K | 2 |
| Xue, Z | 3 |
| Kent, KM | 2 |
| Suddath, WO | 3 |
| Lindsay, J | 2 |
| Giusti, B | 1 |
| Saracini, C | 1 |
| Sestini, I | 1 |
| Dean, J | 1 |
| Yujie, Z | 1 |
| Yingxin, Z | 1 |
| Yuyang, L | 1 |
| Yonghe, G | 1 |
| Wanjun, C | 1 |
| Zheng, C | 1 |
| Berger, PB | 2 |
| Teirstein, PS | 1 |
| Tanguay, JF | 1 |
| Kandzari, DE | 1 |
| Topol, EJ | 1 |
| Butler, MJ | 1 |
| Eccleston, D | 1 |
| Clark, DJ | 1 |
| Ajani, AE | 2 |
| Andrianopoulos, N | 1 |
| Brennan, A | 1 |
| New, G | 1 |
| Black, A | 1 |
| Szto, G | 1 |
| Reid, CM | 1 |
| Yan, BP | 1 |
| Shaw, JA | 1 |
| Dart, AM | 1 |
| Duffy, SJ | 1 |
| Pecot, CV | 1 |
| Fuller, M | 1 |
| Muldowney, JA | 1 |
| Misra, S | 1 |
| Gao, C | 1 |
| Ren, C | 1 |
| Li, D | 1 |
| Li, L | 1 |
| Esposito, RA | 1 |
| Wang, ZJ | 1 |
| Zhou, YJ | 1 |
| Liu, YY | 1 |
| Yu, M | 1 |
| Shi, DM | 1 |
| Zhao, YX | 1 |
| Guo, YH | 1 |
| Cheng, WJ | 1 |
| Nie, B | 1 |
| Ge, HL | 1 |
| Jia, DA | 1 |
| Yang, SW | 1 |
| Yan, ZX | 1 |
| Schulz, S | 2 |
| Schuster, T | 1 |
| Ellert, J | 1 |
| Massberg, S | 2 |
| Goedel, J | 1 |
| Bruskina, O | 1 |
| Ulm, K | 1 |
| Gavini, R | 1 |
| Beauzile, P | 1 |
| Sushinsky, SJ | 1 |
| Scheinowitz, M | 1 |
| Tantry, U | 1 |
| Kent, K | 1 |
| Gurbel, P | 1 |
| Wilson, AM | 1 |
| Brittenden, J | 1 |
| Bachoo, P | 1 |
| Ford, I | 1 |
| Nixon, GF | 1 |
| Geisler, T | 1 |
| Zürn, C | 1 |
| Simonenko, R | 1 |
| Rapin, M | 1 |
| Kraibooj, H | 1 |
| Kilias, A | 1 |
| Bigalke, B | 1 |
| Stellos, K | 1 |
| Schwab, M | 1 |
| May, AE | 1 |
| Herdeg, C | 1 |
| Gawaz, M | 1 |
| Mazighi, M | 1 |
| Saint Maurice, JP | 1 |
| Bresson, D | 1 |
| Szatmary, Z | 1 |
| Houdart, E | 1 |
| Montalescot, G | 1 |
| Hulot, JS | 1 |
| Collet, JP | 1 |
| Yucel, S | 1 |
| Bahcivan, M | 1 |
| Gol, MK | 1 |
| Erenler, BH | 1 |
| Kolbakir, F | 1 |
| Keceligil, HT | 1 |
| Popescu, WM | 1 |
| Chun, KJ | 1 |
| Park, SW | 1 |
| Kim, YH | 1 |
| Yun, SC | 1 |
| Kim, WJ | 2 |
| Lee, JY | 2 |
| Park, DW | 1 |
| Lee, CW | 1 |
| Rhee, KS | 1 |
| Chae, JK | 1 |
| Ko, JK | 1 |
| Park, JH | 1 |
| Lee, JH | 1 |
| Choi, SW | 1 |
| Jeong, JO | 1 |
| Seong, IW | 1 |
| Jon, S | 1 |
| Cho, YH | 1 |
| Lee, NH | 1 |
| Kim, JH | 1 |
| Flores-Ríos, X | 1 |
| Aldama-López, G | 1 |
| Calviño-Santos, RA | 1 |
| Vázquez-González, N | 1 |
| Castro-Beiras, A | 1 |
| Belch, JJ | 1 |
| Dormandy, J | 1 |
| Biasi, GM | 1 |
| Biasi, BM | 1 |
| Cairols, M | 1 |
| Diehm, C | 1 |
| Eikelboom, B | 1 |
| Golledge, J | 1 |
| Jawien, A | 1 |
| Lepäntalo, M | 1 |
| Norgren, L | 1 |
| Hiatt, WR | 1 |
| Becquemin, JP | 2 |
| Bergqvist, D | 2 |
| Clement, D | 1 |
| Baumgartner, I | 1 |
| Minar, E | 1 |
| Stonebridge, P | 1 |
| Vermassen, F | 1 |
| Matyas, L | 1 |
| Leizorovicz, A | 1 |
| Harmsze, AM | 2 |
| van Werkum, JW | 2 |
| Bouman, HJ | 2 |
| Breet, NJ | 2 |
| van 't Hof, AW | 1 |
| Ruven, HJ | 1 |
| Hackeng, CM | 2 |
| Klungel, OH | 1 |
| de Boer, A | 1 |
| Deneer, VH | 1 |
| Gao, G | 1 |
| Zheng, Z | 1 |
| Pi, Y | 1 |
| Lu, B | 1 |
| Hu, S | 1 |
| Sun, JC | 1 |
| Teoh, KH | 1 |
| Lamy, A | 1 |
| Sheth, T | 1 |
| Ellins, ML | 1 |
| Jung, H | 1 |
| Yusuf, S | 1 |
| Anand, S | 1 |
| Connolly, S | 1 |
| Whitlock, RP | 1 |
| Eikelboom, JW | 1 |
| Kozuma, K | 1 |
| Ota, Y | 1 |
| Nagai, Y | 1 |
| Katsuta, Y | 1 |
| Nozaki, E | 1 |
| Onodera, T | 1 |
| Ikari, Y | 2 |
| Kotani, J | 1 |
| Kyo, E | 1 |
| Yokoi, H | 1 |
| Nakamura, M | 2 |
| Mayer, K | 1 |
| Refiker, M | 1 |
| Conte, MS | 2 |
| Koul, S | 1 |
| Smith, JG | 1 |
| Scherstén, F | 1 |
| James, S | 1 |
| Lagerqvist, B | 1 |
| Erlinge, D | 1 |
| Gaglia, MA | 1 |
| Gasparovic, H | 1 |
| Petricevic, M | 1 |
| Biocina, B | 1 |
| Bisdas, T | 1 |
| Haverich, A | 1 |
| Teebken, OE | 1 |
| Avlonitis, VS | 1 |
| Planas, S | 1 |
| Hayes, AM | 1 |
| Parry, A | 1 |
| Warner, TD | 1 |
| Mitchell, JA | 1 |
| Kirkby, NS | 1 |
| Sambu, N | 1 |
| Radhakrishnan, A | 1 |
| Dent, H | 1 |
| Calver, AL | 1 |
| Corbett, S | 1 |
| Gray, H | 1 |
| Simpson, IA | 1 |
| Curzen, N | 1 |
| Monaco, M | 1 |
| Di Tommaso, L | 1 |
| Pinna, GB | 1 |
| Lillo, S | 1 |
| Schiavone, V | 1 |
| Stassano, P | 1 |
| Kizilkilic, O | 1 |
| Kocer, N | 1 |
| Metaxas, GE | 1 |
| Babic, D | 1 |
| Homan, R | 1 |
| Islak, C | 1 |
| Kang, J | 1 |
| Park, JJ | 1 |
| Yang, HM | 1 |
| Lee, HY | 1 |
| Kang, HJ | 1 |
| Koo, BK | 1 |
| Oh, BH | 1 |
| Park, YB | 1 |
| Charlot, M | 1 |
| Nielsen, LH | 1 |
| Lindhardsen, J | 1 |
| Ahlehoff, O | 1 |
| Olsen, AM | 1 |
| Hansen, ML | 1 |
| Hansen, PR | 1 |
| Madsen, JK | 1 |
| Køber, L | 1 |
| Gislason, GH | 1 |
| Torp-Pedersen, C | 1 |
| Jang, JS | 1 |
| Jin, HY | 1 |
| Seo, JS | 1 |
| Yang, TH | 1 |
| Kim, DK | 2 |
| Kim, DS | 1 |
| Seol, SH | 1 |
| Kim, DI | 1 |
| Cho, KI | 1 |
| Kim, BH | 1 |
| Park, YH | 1 |
| Je, HG | 1 |
| Jeong, YH | 1 |
| Borghesi, M | 1 |
| Tebaldi, M | 1 |
| Parrinello, G | 1 |
| Ferrari, R | 1 |
| Pinnow, E | 1 |
| Cheneau, E | 1 |
| Leborgne, L | 1 |
| Dieble, R | 1 |
| Bui, AB | 1 |
| Kent, KK | 1 |
| Kim, MH | 1 |
| Cha, KS | 1 |
| Han, JY | 1 |
| Kim, HJ | 1 |
| Kim, JS | 1 |
| Krötz, F | 1 |
| Schiele, TM | 1 |
| Zahler, S | 1 |
| König, A | 1 |
| Rieber, J | 1 |
| Kantlehner, R | 1 |
| Pöllinger, B | 1 |
| Dühmke, E | 1 |
| Theisen, K | 1 |
| Sohn, HY | 1 |
| Klauss, V | 1 |
| Mueller, C | 1 |
| Roskamm, H | 1 |
| Hunziker, P | 1 |
| Marsch, S | 1 |
| Perruchoud, A | 1 |
| Buettner, HJ | 1 |
| Strike, PC | 1 |
| Robinson, NM | 1 |
| Dymond, DS | 1 |
| Shechter, M | 1 |
| Ortolani, P | 1 |
| Marzocchi, A | 1 |
| Gaiba, W | 1 |
| Neri, S | 1 |
| Marrozzini, C | 1 |
| Aquilina, M | 1 |
| Branzi, A | 1 |
| Smout, JD | 1 |
| Mikhailidis, DP | 1 |
| Shenton, BK | 1 |
| Stansby, G | 1 |
| Jiménez-Quevedo, P | 1 |
| Bernardo, E | 1 |
| Sabaté, M | 2 |
| Stiefelhagen, P | 1 |
| Stein, PD | 2 |
| Schünemann, HJ | 1 |
| Dalen, JE | 2 |
| Gutterman, D | 1 |
| Tielliu, IF | 1 |
| Verhoeven, EL | 1 |
| Zeebregts, CJ | 1 |
| Prins, TR | 1 |
| Span, MM | 1 |
| van den Dungen, JJ | 1 |
| Takeyasu, N | 1 |
| Watanabe, S | 1 |
| Noguchi, Y | 1 |
| Ishikawa, K | 1 |
| Fumikura, Y | 1 |
| Yamaguchi, I | 1 |
| Mehta, SR | 1 |
| Aranki, SF | 1 |
| Michowitz, Y | 1 |
| Blatt, A | 1 |
| Frimmerman, A | 1 |
| Finkelstein, A | 1 |
| Massachi, R | 1 |
| Herz, I | 1 |
| Krakover, R | 1 |
| Miller, H | 1 |
| Keren, G | 1 |
| George, J | 1 |
| Wolak, A | 1 |
| Zahger, D | 1 |
| Ouriel, K | 1 |
| Wholey, MH | 1 |
| Fayad, P | 1 |
| Katzen, BT | 1 |
| Whitlow, P | 1 |
| Frentzko, M | 1 |
| Kuntz, RE | 2 |
| Wechsler, L | 1 |
| Hopkins, N | 1 |
| Satler, L | 1 |
| Mishkel, G | 1 |
| Yadav, JS | 2 |
| Bocek, P | 1 |
| Dember, LM | 2 |
| Kaufman, JS | 2 |
| Beck, GJ | 2 |
| Dixon, BS | 2 |
| Gassman, JJ | 2 |
| Greene, T | 2 |
| Himmelfarb, J | 2 |
| Hunsicker, LG | 1 |
| Kusek, JW | 2 |
| Lawson, JH | 1 |
| Middleton, JP | 1 |
| Radeva, M | 1 |
| Schwab, SJ | 1 |
| Whiting, JF | 1 |
| Feldman, HI | 2 |
| Kuchulakanti, PK | 1 |
| Chu, WW | 1 |
| Ohlmann, P | 1 |
| Rha, SW | 1 |
| Clavijo, LC | 1 |
| Kim, SW | 1 |
| Bui, A | 1 |
| Gevorkian, N | 1 |
| Smith, K | 1 |
| Fournadjieva, J | 1 |
| Jai Shankar, K | 1 |
| Jaiswal, P | 1 |
| Cherian, KM | 1 |
| Ibrahim, K | 1 |
| Tjomsland, O | 1 |
| Halvorsen, D | 1 |
| Wiseth, R | 1 |
| Wahba, A | 1 |
| Karevold, A | 1 |
| Haaverstad, R | 1 |
| Hata, M | 1 |
| Sezai, A | 1 |
| Niino, T | 1 |
| Yoda, M | 1 |
| Wakui, S | 1 |
| Chiku, M | 1 |
| Takayama, T | 1 |
| Honye, J | 1 |
| Saitoh, S | 1 |
| Minami, K | 1 |
| Luxembourg, B | 1 |
| Mani, H | 1 |
| Toennes, SW | 1 |
| Strubel, G | 1 |
| Klaeffling, C | 1 |
| Daemgen-von Brevern, G | 1 |
| Geisen, C | 1 |
| Lindhoff-Last, E | 1 |
| Prabhakaran, S | 1 |
| Wells, KR | 1 |
| Lee, VH | 1 |
| Flaherty, CA | 1 |
| Lopes, DK | 1 |
| Srinivasan, M | 1 |
| Smith, D | 1 |
| Allon, M | 1 |
| Delmez, JA | 1 |
| Greenberg, A | 1 |
| Vazquez, MA | 1 |
| Radeva, MK | 1 |
| Braden, GL | 1 |
| Ikizler, TA | 1 |
| Rocco, MV | 1 |
| Davidson, IJ | 1 |
| Meyers, CM | 1 |
| Tonelli, M | 1 |
| Garrido García, H | 1 |
| Rivas Marín, J | 1 |
| Vilaplana Serrano, F | 1 |
| Martín Infante, A | 1 |
| Lindblad, B | 1 |
| Wakefield, TW | 1 |
| Stanley, TJ | 1 |
| Nichol, BJ | 1 |
| Greenfield, LJ | 1 |
| Stanley, JC | 1 |
| Bergentz, SE | 1 |
| Basile, AP | 1 |
| Fiala, TG | 1 |
| Yaremchuk, MJ | 1 |
| May, JW | 1 |
| Sainsous, J | 1 |
| Silvestri, M | 1 |
| Bouvier, JL | 1 |
| Comet, B | 1 |
| Siméoni, JB | 1 |
| Villain, P | 1 |
| Pietri, P | 1 |
| Quatre, JM | 1 |
| Bayet, G | 1 |
| Hanaoka, T | 1 |
| Eeckhout, E | 1 |
| Kappenberger, L | 1 |
| Goy, JL | 1 |
| Simoni, G | 1 |
| Galleano, R | 1 |
| Civalleri, D | 1 |
| Decian, F | 1 |
| Desalvo, P | 1 |
| Ceppa, P | 1 |
| Baccini, P | 1 |
| Lenti, E | 1 |
| Bachi, V | 1 |
| Belkin, M | 1 |
| Donaldson, MC | 1 |
| Whittemore, AD | 1 |
| Gröntoft, KC | 2 |
| Larsson, R | 1 |
| Mulec, H | 2 |
| Weiss, LG | 1 |
| Dickinson, JP | 1 |
| Makkar, RR | 1 |
| Eigler, NL | 1 |
| Kaul, S | 1 |
| Frimerman, A | 1 |
| Shah, PK | 1 |
| Forrester, JS | 1 |
| Herbert, JM | 1 |
| Litvack, F | 1 |
| Goldman, S | 1 |
| Théroux, P | 1 |
| Jackson, MR | 1 |
| Clagett, GP | 1 |
| Reifart, N | 1 |
| Störger, H | 1 |
| Schwarz, F | 1 |
| Rabe, A | 1 |
| Siegerstetter, V | 1 |
| Huber, M | 1 |
| Ochs, A | 1 |
| Blum, HE | 1 |
| Rössle, M | 1 |
| Wardeh, AJ | 1 |
| Kay, IP | 2 |
| Coen, VL | 1 |
| Gijzel, AL | 1 |
| Ligthart, JM | 1 |
| den Boer, A | 1 |
| Levendag, PC | 1 |
| van Der Giessen, WJ | 1 |
| Serruys, PW | 1 |
| Yoon, Y | 1 |
| Shim, WH | 1 |
| Lee, DH | 1 |
| Pyun, WB | 1 |
| Kim, IJ | 1 |
| Cho, SY | 1 |
| Van Langenhove, G | 2 |
| Vermeersch, P | 2 |
| Vaerenberg, M | 1 |
| Heuten, H | 1 |
| Stockman, D | 2 |
| Convens, C | 2 |
| Albertal, M | 2 |
| Vrints, C | 1 |
| Van den Branden, F | 2 |
| Van den Heuvel, P | 2 |
| Serrano, P | 1 |
| Kutryk, MJ | 1 |
| Vanagt, E | 1 |
| Gottsauner-Wolf, M | 1 |
| Zasmeta, G | 1 |
| Hornykewycz, S | 1 |
| Nikfardjam, M | 1 |
| Stepan, E | 1 |
| Wexberg, P | 1 |
| Zorn, G | 1 |
| Glogar, D | 1 |
| Probst, P | 1 |
| Maurer, G | 1 |
| Dillon, WC | 1 |
| Eckert, GJ | 1 |
| Dillon, JC | 1 |
| Ritchie, ME | 1 |
| Dieter, RS | 1 |
| Dirschinger, J | 1 |
| Dotzer, F | 1 |
| von Welser, N | 1 |
| Kiesz, RS | 1 |
| Buszman, P | 1 |
| Martin, JL | 1 |
| Deutsch, E | 1 |
| Rozek, MM | 1 |
| Gaszewska, E | 1 |
| Rewicki, M | 1 |
| Seweryniak, P | 1 |
| Kosmider, M | 1 |
| Tendera, M | 1 |
| Shin, EK | 1 |
| Son, JW | 1 |
| Sohn, MS | 1 |
| Jin, DK | 1 |
| Park, GS | 1 |
| Koh, KK | 1 |
| Ahn, TH | 1 |
| Choi, IS | 1 |
| Cutlip, DE | 1 |
| Baim, DS | 1 |
| Ho, KK | 1 |
| Popma, JJ | 1 |
| Lansky, AJ | 1 |
| Cohen, DJ | 1 |
| Carrozza, JP | 1 |
| Chauhan, MS | 1 |
| Rodriguez, O | 1 |
| Kuroda, Y | 1 |
| Hara, K | 1 |
| Nakajima, H | 1 |
| Mukherjee, D | 1 |
| Chew, DP | 1 |
| Robbins, M | 1 |
| Raymond, RE | 1 |
| Moliterno, DJ | 1 |
| Marx, SO | 1 |
| Marks, AR | 1 |
| Zurbrügg, HR | 1 |
| Musci, M | 1 |
| Sänger, S | 1 |
| Gutersohn, A | 1 |
| Mülling, C | 1 |
| Wellnhofer, E | 1 |
| Schaffner, T | 1 |
| Hetzer, R | 1 |
| Duran, E | 1 |
| Canbaz, S | 1 |
| Ege, T | 1 |
| Acipayam, M | 1 |
| Piamsomboon, C | 1 |
| Laothavorn, P | 1 |
| Chatlaong, B | 1 |
| Saguanwong, S | 1 |
| Nasawadi, C | 1 |
| Tanprasert, P | 1 |
| Leelaprute, M | 1 |
| Intayakorn, U | 1 |
| Amornsak, N | 1 |
| Kambayashi, J | 2 |
| Watase, M | 2 |
| Itoh, T | 2 |
| Kawasaki, T | 2 |
| Shiba, E | 2 |
| Sakon, M | 2 |
| Mori, T | 2 |
| Sagnol, P | 1 |
| Delahaye, JP | 1 |
| Mantz, F | 1 |
| Freund, M | 1 |
| Cazenave, JP | 1 |
| Limet, R | 2 |
| David, JL | 2 |
| Magotteaux, P | 1 |
| Larock, MP | 1 |
| Rigo, P | 1 |
| Harker, LA | 2 |
| Verstraete, M | 1 |
| Brown, BG | 1 |
| Chesebro, JH | 1 |
| Ekeström, S | 1 |
| Henderson, AH | 1 |
| Jewitt, DE | 1 |
| Oliver, MF | 1 |
| Sleight, P | 1 |
| Kawana, S | 1 |
| Katori, M | 1 |
| Ohta, M | 1 |
| Nishiyama, S | 1 |
| Hansen, KJ | 1 |
| Howe, HR | 1 |
| Edgerton, TA | 1 |
| Faust, KB | 1 |
| Kon, ND | 1 |
| Geisinger, KR | 1 |
| Meredith, JH | 1 |
| Fiskerstrand, CE | 1 |
| Thompson, IW | 1 |
| Burnet, ME | 1 |
| Williams, P | 1 |
| Anderton, JL | 1 |
| Rothlin, ME | 1 |
| Pfluger, N | 1 |
| Speiser, K | 1 |
| Goebel, N | 1 |
| Krayenbühl, HP | 1 |
| Steinbrunn, W | 1 |
| Turina, M | 1 |
| Senning, A | 1 |
| Gutierrez, A | 1 |
| Olander, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Dipyridamole Plus Aspirin on Hemodialysis Graft Patency[NCT00067119] | Phase 3 | 649 participants (Actual) | Interventional | 2003-01-01 | Completed | ||
| Impact of Vitamin D on Arteriovenous Fistulae Maturation Among ESRD Patients[NCT00912782] | 52 participants (Actual) | Interventional | 2009-01-31 | Completed | |||
| Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of a Single Dose of PRT-201 Administered Immediately After Arteriovenous Graft Creation in Patients With Chronic Kidney Disease[NCT01001351] | Phase 1/Phase 2 | 89 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| Impact of Preoperative FFR on Arterial Bypass Graft Functionality: Towards a New CABG Paradigm[NCT02527044] | 120 participants (Anticipated) | Interventional | 2015-11-30 | Active, not recruiting | |||
| Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?[NCT00228423] | Phase 2 | 113 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| RESOLUTE International Registry: Evaluation of the Resolute Zotarolimus-Eluting Stent System in a 'Real-World' Patient Population[NCT00752128] | 2,349 participants (Actual) | Observational | 2008-08-31 | Completed | |||
| Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835] | 1,492 participants (Anticipated) | Observational [Patient Registry] | 2019-08-01 | Recruiting | |||
| A Clinical Evaluation of the Medtronic Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2mm[NCT00726453] | 1,516 participants (Actual) | Interventional | 2008-07-31 | Completed | |||
| The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries[NCT00927940] | 100 participants (Actual) | Interventional | 2009-03-31 | Completed | |||
| RESOLUTE-III All-comers Trial: A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention[NCT00617084] | Phase 4 | 2,292 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| PROTECT Trial: Patient Related OuTcomes With Endeavor Versus Cypher Stenting Trial[NCT00476957] | Phase 4 | 8,709 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inh[NCT00391872] | Phase 3 | 18,624 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Phase III, Multi-Center Randomized, Double-Blind, Placebo-Controlled Trial of the Ex Vivo Treatment With CGT003 of Coronary Vein Grafts in Patients Undergoing Coronary Artery Bypass Graft Procedures[NCT00042081] | Phase 3 | 3,000 participants | Interventional | 2002-07-31 | Completed | ||
| Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry[NCT01515345] | Phase 3 | 1,008 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Randomized, Double-Blind, Placebo-controlled Trial of 6 vs. 12 Months Clopidogrel Therapy After Implantation of a Drug-Eluting Stent[NCT00661206] | Phase 4 | 4,005 participants (Actual) | Interventional | 2008-09-30 | Active, not recruiting | ||
| A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX)[NCT01156571] | Phase 3 | 11,145 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY[NCT00611286] | Phase 4 | 1,700 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| Ticagrelor Versus High-dose Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Percutaneous Coronary Intervention: The PL-PLATELET Randomized Trial[NCT03078465] | Phase 3 | 0 participants (Actual) | Interventional | 2017-06-20 | Withdrawn (stopped due to Competitive studies were conducted at the same time, and enrollment was suspended.) | ||
| Optimization of Antiplatelet Therapy With Clopidogrel on the Basis of the Extent of Platelet Inhibition in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy Undergoing PCI With Stent Implantation[NCT00774475] | Phase 3 | 442 participants (Anticipated) | Interventional | 2008-11-30 | Not yet recruiting | ||
| ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation (The RAPID GENE Study)[NCT01184300] | Phase 2/Phase 3 | 200 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety[NCT00645918] | 2,800 participants (Actual) | Interventional | 2008-06-30 | Completed | |||
| Intra-patient Randomized Study With Polymer Free Drug Eluting Stent Versus Abluminal Biodegradable Polymer Drug Eluting Stent With Early OCT Follow up[NCT02785237] | 70 participants (Actual) | Interventional | 2016-06-30 | Completed | |||
| Antiplatelet Resistance Research in Patients With Peripheral Arterial Revascularization[NCT03953547] | 88 participants (Actual) | Observational | 2018-01-01 | Completed | |||
| Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242] | Phase 4 | 9,006 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid (ASA) After Percutaneous Lower Extremity Revascularization in Patients With Peripheral Arterial Disease[NCT02798913] | Phase 3 | 300 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| A Double-blind, Randomized Study of Clopidogrel 75 mg/d vs Placebo, on a Background of ASA 75-100 mg/d,in Peripheral Arterial Disease (PAD) Patients Receiving a Unilateral Below Knee Bypass Graft.[NCT00174759] | Phase 3 | 1,460 participants (Anticipated) | Interventional | 2004-09-30 | Completed | ||
| Cost-effectiveness of CYP2C19 Genotype Guided Treatment With Antiplatelet Drugs in Patients With ST-segment-elevation Myocardial Infarction Undergoing Immediate PCI With Stent Implantation: Optimization of Treatment (POPular Genetics).[NCT01761786] | Phase 4 | 2,700 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| [NCT00776477] | Phase 3 | 300 participants (Anticipated) | Interventional | 2007-12-31 | Recruiting | ||
| Pilot Study of Preoperative Aspirin and Postoperative Clopidogrel's Effects on Graft Patency and Cardiac Events in Coronary Artery Bypass Surgery[NCT00330772] | Phase 3 | 150 participants (Anticipated) | Interventional | 2006-07-31 | Completed | ||
| Do Point-of-care Platelet Function Assays Predict Clinical Outcomes in Clopidogrel Pre-treated Patients Undergoing Elective PCI. (The POPular Study)[NCT00352014] | 1,000 participants (Anticipated) | Observational | 2006-01-31 | Completed | |||
| Long Term Safety Study in Patients Included in the CLARINET Study With Cyanotic Congenital Heart Disease Palliated With a Systemic-to-pulmonary Artery Shunt and for Whom the Shunt is Still in Place at One Year of Age[NCT00833703] | Phase 3 | 49 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Double-blind, Randomized, Placebo Controlled Pilot Trial to Evaluate the Safety and Efficacy of Vorapaxar in Maturation of Arteriovenous Fistulae for Hemodialysis Access[NCT02475837] | Phase 2 | 17 participants (Actual) | Interventional | 2015-08-26 | Completed | ||
| Effect of Clopidogrel on Early Failure of Arteriovenous Fistulas for Hemodialysis[NCT03289520] | Phase 3 | 877 participants (Actual) | Interventional | 2003-01-07 | Completed | ||
| Clinical Evaluation of a Vascular Venous Anastomotic Connector for Minimally Invasive Connection of an Arteriovenous Graft for Hemodialysis [InterGraft VIG-only Study][NCT02532621] | 158 participants (Actual) | Interventional | 2018-02-21 | Completed | |||
| Randomized Controlled Trial Comparing endoAVF Versus surgAVF[NCT05654103] | 90 participants (Anticipated) | Interventional | 2024-02-01 | Not yet recruiting | |||
| Short-Term Endogenous Hydrogen Sulfide Upregulation For Vein Graft Disease[NCT05457881] | 226 participants (Anticipated) | Interventional | 2024-03-01 | Not yet recruiting | |||
| Effects of Heparin on Early Patency of Arteriovenous Fistula in Angioaccess Surgery of Patients With End-Stage Renal Disease[NCT02493504] | Phase 4 | 150 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| A Randomized Comparison of Low-dose Versus High-dose Rosuvastatin on Optical Coherence Tomography Based Early Vascular Healing for Patients With Acute Coronary Syndrome[NCT03007524] | Phase 4 | 80 participants (Anticipated) | Interventional | 2016-07-31 | Recruiting | ||
| Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery[NCT03445273] | 1,800 participants (Anticipated) | Observational [Patient Registry] | 2018-11-21 | Not yet recruiting | |||
| A Multicenter, Open-labeled, Randomized Controlled Trial Comparing Three 2nd Generation Drug-Eluting Stents in Real-World Practice[NCT01397175] | 1,960 participants (Actual) | Interventional | 2013-01-16 | Terminated (stopped due to Slow enrollment) | |||
| Cardiac Allograft Remodeling and Effects of Sirolimus on Its Progression[NCT01889992] | Phase 1 | 42 participants (Actual) | Interventional | 2013-04-24 | Terminated (stopped due to PI left University and project not continued) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Maturation of an AVF is the ability to stick the AVF with two large bore needles at ≥ 6 consecutive dialysis sessions, and achievement of an AVF blood flow >300 ml/min, assessed at six months following AVF creation. (NCT00912782)
Timeframe: 6 months
| Intervention | percentage of group (Number) |
|---|---|
| Placebo | 50 |
| Cholecalciferol | 40 |
(NCT00912782)
Timeframe: 10 weeks
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Serum 25 (OH) D | Serum Calcium | |
| Cholecalciferol | 53.4 | 8.8 |
| Placebo | 18.4 | 9.1 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 4 |
| Placebo | 5 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 1 |
| Placebo | 0 |
Postoperative angiogram 12 months post-CABG (NCT00228423)
Timeframe: One year following surgery
| Intervention | percentage (Number) |
|---|---|
| 75mg Clopidogrel | 94.3 |
| Placebo | 93.2 |
IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed (NCT00228423)
Timeframe: One year following surgery
| Intervention | mm (Mean) |
|---|---|
| 75mg Clopidogrel | 4.1 |
| Placebo | 4.5 |
(NCT00752128)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Cardiac Death or Target Vessel MI | 4.2 |
(NCT00752128)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Overall Stent Thrombosis (Definite and Probable-ARC) | 0.9 |
(NCT00726453)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Primary Enrollment Group | 1.3 |
Major Adverse Cardiac Event (MACE) composite endpoint and each individual component (death, Target Vessel MI (Q wave and non-Q wave), emergent coronary bypass surgery (CABG), or clinically-driven repeat Target Lesion Revascularization (TLR) by percutaneous or surgical methods). (NCT00726453)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Primary Enrollment Group | 5.5 |
Stent Thrombosis (ST) (as determined by historic and ARC definitions). (NCT00726453)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Primary Enrollment Group | 0.1 |
Target Lesion Failure (TLF) at 12 months post-procedure, defined as Cardiac Death, Target Vessel Myocardial Infarction (TVMI) (Q wave and non-Q wave) or clinically-driven Target Lesion Revascularization (TLR) by percutaneous or surgical methods. (NCT00726453)
Timeframe: 12 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Primary Enrollment Group | 4.7 |
Target Vessel Failure (TVF) composite endpoint and each individual component (Cardiac Death, Target Vessel MI, or clinically-driven Target Vessel Revascularization (TVR) by percutaneous or surgical methods). (NCT00726453)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Primary Enrollment Group | 6.3 |
Target Vessel MI (as determined by extended historical and ARC definitions). (NCT00726453)
Timeframe: 12 months
| Intervention | percentage of eligible participants (Number) |
|---|---|
| Primary Enrollment Group | 1.4 |
The difference between the post-procedure immediate minimal lumen diameter (MLD) and follow up angigraphy MLD (NCT00927940)
Timeframe: Post procedure, 8 Months
| Intervention | mm (Mean) |
|---|---|
| Zotarolimus Eluting Stent | 0.13 |
Major Secondary Endpoint Target lesion fature (TLF) is defined as cardiac death, target vessel myocardial infarction(Q wave and non-Q wave), or clinically-driven target lesion revascularization (TLR) by percutaneous or surgical methods. (NCT00927940)
Timeframe: 12 months
| Intervention | percentage of participants with TLF (Number) |
|---|---|
| Zotarolims Eluting Stent | 4.0 |
In Stent Percent Diameter Stenosis at thirteen months. In Stent Percent Diameter Stenosis: measured percent of diameter stenosis at the region of the stent (calculated as 100x(RVD-MLD)/RVD using the mean values from 2 orthogonal views by QCA. RVD (Reference Vessel Diameter): average of normal segments within 10mm proximal and distal to target lesion from 2 orthogonal views using QCA. MLD (Minimal Lumen Diameter): average of 2 orthogonal views of the narrowest point wihtin the area of assessment. MLD measured during QCA by the angiographic core laboratory. (NCT00617084)
Timeframe: 13 Months
| Intervention | Percentage diameter stenosis (Mean) |
|---|---|
| 1. Resolute - 12-13 Months | 21.65 |
| 2. XIENCE V - 12-13 Months | 19.76 |
Percentage of participants that had either Cardiac Death, Myocardial Infarction (not clearly attributable to a non-target vessel)or Target Lesion Revascularization (TLR, clinically indicated) after one year. MI: Q MI if new pathological Q waves and chest pain, non Q MI if CK elevated more than two times normal, troponin elevated more than normal, according to ARC definitions. TLR, clinically indicated if associated with ischemic symptoms and angiographic min lumen diameter bigger than fifty percent by QCA or without symptoms and min lumen diameter bigger than seventy percent. Measure average. (NCT00617084)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| 1. Resolute - 12-13 Months | 8.2 |
| 2. XIENCE V - 12-13 Months | 8.3 |
Definite or probable stent thrombosis rate. (NCT00476957)
Timeframe: 3 years
| Intervention | participants (Number) |
|---|---|
| E-ZES | 61 |
| C-SES | 75 |
Total death and large non-fatal myocardial infarctions Total death and non-fatal myocardial infarctions Cardiac death and large non-fatal MI Cardiac death and non-fatal myocardial infarctions (NCT00476957)
Timeframe: 3 years
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Total death and large non-fatal myocardial infarct | Total death and non-fatal myocardial infarctions | Cardiac death and large non-fatal MI | Cardiac death and non-fatal MI | Target lesion revascularization | Stroke | Bleeding events | |
| C-SES | 255 | 360 | 174 | 282 | 156 | 72 | 184 |
| E-ZES | 225 | 331 | 157 | 265 | 249 | 77 | 201 |
Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 901 |
| CLOPIDOGREL | 1065 |
Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1290 |
| CLOPIDOGREL | 1456 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 569 |
| CLOPIDOGREL | 668 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 864 |
| CLOPIDOGREL | 1014 |
Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 961 |
| CLOPIDOGREL | 929 |
Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 619 |
| CLOPIDOGREL | 654 |
Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 329 |
| CLOPIDOGREL | 341 |
Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 399 |
| CLOPIDOGREL | 506 |
Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 353 |
| CLOPIDOGREL | 442 |
Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1339 |
| CLOPIDOGREL | 1215 |
Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 504 |
| CLOPIDOGREL | 593 |
Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 362 |
| CLOPIDOGREL | 306 |
Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 235 |
| CLOPIDOGREL | 180 |
Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 125 |
| CLOPIDOGREL | 106 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 21 |
| CLOPIDOGREL | 16 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 84 |
| CLOPIDOGREL | 51 |
"Bleeding classified by the TIMI hemorrhage classification scheme:~Minor: any clinically overt sign of hemorrhage (including imaging) that is associated with a hemoglobin drop of 3 to < 5 g/dL~Major: (1) if it is intracranial, or (2) clinically significant overt signs of hemorrhage associated with a drop inhemoglobin of > 5 g/dL" (NCT01515345)
Timeframe: 30days
| Intervention | participants (Number) |
|---|---|
| Standard Therapy | 17 |
| Individualized Therapy | 9 |
"The angiographic or pathological confirmation of stent thrombosis is called definite stent thrombosis" (NCT01515345)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Standard Therapy | 1 |
| Individualized Therapy | 0 |
"Probable stent thrombosis is considered to have occurred in case of~any unexplained death within the first 30 days.~any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause, irrespective of the time after the index procedure" (NCT01515345)
Timeframe: 30days
| Intervention | participants (Number) |
|---|---|
| Standard Therapy | 2 |
| Individualized Therapy | 0 |
Clinical Events Committee (CEC)-adjudicated results (modified intent-to-treat [mITT] population) (NCT01156571)
Timeframe: 48 hours after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Treatment Arm | 257 |
| Clopidogrel Treatment Arm | 322 |
GUSTO = Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries trial (NCT01156571)
Timeframe: 48 hours after randomization
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| GUSTO severe/life threatening | GUSTO moderate | GUSTO severe or moderate | TIMI major | TIMI minor | TIMI major or minor | Any blood transfusion | |
| Cangrelor Treatment Arm | 9 | 22 | 31 | 5 | 9 | 14 | 25 |
| Clopidogrel Treatment Arm | 6 | 13 | 19 | 5 | 3 | 8 | 16 |
CEC-adjudicated results (mITT population) (NCT01156571)
Timeframe: 48 hours after randomization
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Stent Thrombosis | Death | MI (myocardial infarction) | IDR (ischemia-driven revascularization) | |
| Cangrelor Treatment Arm | 46 | 18 | 207 | 28 |
| Clopidogrel Treatment Arm | 74 | 18 | 255 | 38 |
Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 141 |
| Aspirin + Ticagrelor | 250 |
Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 135 |
| Aspirin + Ticagrelor | 137 |
For all reported bleeding events, the type and the etiology of the bleeding event were collected. Participants who experienced bleeding events during the 'on-treatment period' were counted by bleeding type and etiology. (NCT00833703)
Timeframe: Up to a maximum of 6 months
| Intervention | participants (Number) | |
|---|---|---|
| Spontaneous | Puncture (vascular access site) | |
| Clopidogrel 0.2 mg/kg/Day | 1 | 1 |
| Placebo | 0 | 0 |
"All bleeding events experienced during the study period were collected as for any Adverse Event.~The 'on-treatment' period was defined as the period from inclusion in the extension study up to 28 days after treatment discontinuation, and participants who experienced bleeding events during that period were counted." (NCT00833703)
Timeframe: Up to a maximum of 6 months
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Any bleeding event | - Serious | - Serious with an outcome of death | - Leading to permanent treatment discontinuation | |
| Clopidogrel 0.2 mg/kg/Day | 2 | 0 | 0 | 0 |
| Placebo | 0 | 0 | 0 | 0 |
"Outcome events, shunt thrombosis requiring intervention or death, experienced during the study period were recorded.~Participants were counted excluding the events that occured after the participant's protocol study end (occurrence of shunt thrombosis, next surgical procedure for correction of the congenital heart disease, death, or 18 months of age, whichever came first)." (NCT00833703)
Timeframe: Up to a maximum of 6 months
| Intervention | participants (Number) | |
|---|---|---|
| shunt thrombosis requiring intervention | death | |
| Clopidogrel 0.2 mg/kg/Day | 0 | 0 |
| Placebo | 0 | 1 |
Bleeding events according to GUSTO (criteria for bleeding: Severe, Moderate or Mild) and BARC (bleeding criteria Type 0-5, with 0 being no bleeding and 5 referring to probable or definite fatal bleeding) Criteria (NCT02475837)
Timeframe: up to 238 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Vorapaxar Intervention | 0 |
| Placebo Intervention | 1 |
Participants able to use their AV fistula for dialysis within 180 days of surgery were considered to have met the outcome. (NCT02475837)
Timeframe: up to 238 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Vorapaxar Intervention | 2 |
| Placebo Intervention | 4 |
Criteria for outcome: AV fistula patency at 150-180 days, with at least 50% increase in vein diameter by ultrasound compared with preoperative vein diameter measurement. (NCT02475837)
Timeframe: 150-238 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Vorapaxar Intervention | 1 |
| Placebo Intervention | 5 |
Time to AV fistula functional maturation (defined as successful cannulation of the AV fistula for six hemodialysis sessions within three weeks). (NCT02475837)
Timeframe: up to 238 days
| Intervention | Days to functional maturation (Median) |
|---|---|
| Vorapaxar Intervention | 169 |
| Placebo Intervention | 145 |
19 reviews available for ticlopidine and Graft Occlusion, Vascular
| Article | Year |
|---|---|
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans; | 2021 |
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans; | 2021 |
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans; | 2021 |
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans; | 2021 |
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans; | 2021 |
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans; | 2021 |
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans; | 2021 |
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans; | 2021 |
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans; | 2021 |
Dual anti-platelet therapy after coronary artery bypass grafting: is there any benefit? A systematic review and meta-analysis.
Topics: Angina Pectoris; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Graft Occl | 2013 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Clinical Trials as Topic; Clopidogrel; Coronary Thrombosis; Death, | 2014 |
Wandering stent within the pulmonary circulation.
Topics: Aged, 80 and over; Angiography, Digital Subtraction; Anticoagulants; Arteriovenous Shunt, Surgical; | 2014 |
Resistance to antiplatelet drugs: what progress has been made?
Topics: Aspirin; Clopidogrel; Graft Occlusion, Vascular; Hemorrhage; Humans; Percutaneous Coronary Intervent | 2014 |
Use of antiplatelet drugs after cardiac operations.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Administration Schedule; Drug Therapy, Combinatio | 2014 |
Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention.
Topics: Aged; Clopidogrel; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Male; Percutaneous Coronar | 2015 |
Genetic polymorphisms influence on the response to clopidogrel in peripheral artery disease patients following percutaneous transluminal angioplasty.
Topics: Aged; Angioplasty; Atherosclerosis; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Cyto | 2016 |
Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.
Topics: Acute Coronary Syndrome; Analysis of Variance; Aspirin; Blood Vessel Prosthesis Implantation; Clopid | 2017 |
Antiplatelet therapy after endovascular intervention: does combination therapy really work and what is the optimum duration of therapy?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis Implantation; Cardiovascular Diseas | 2009 |
Systematic review of thienopyridine discontinuation and its impact upon clinical outcomes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Administration Schedule; | 2011 |
A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation.
Topics: Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cilostazol; Clopidogrel; Com | 2012 |
Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Aspirin; Clopidogrel; Contraindications; Coronary Artery Bypass; Coronary Disease; Dose-Response Rel | 2004 |
Balancing the benefit and risk of oral antiplatelet agents in coronary artery bypass surgery.
Topics: Administration, Oral; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Coron | 2005 |
Stents for intracoronary placement: current status and future directions.
Topics: Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Artery Bypass; Coronary Disease; Coro | 1996 |
Antithrombotic therapy in peripheral arterial occlusive disease.
Topics: Angioplasty, Balloon, Coronary; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Endarterectomy, C | 1998 |
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Causality; Coronary Disease; Coronary Thrombosis; End | 2001 |
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Causality; Coronary Disease; Coronary Thrombosis; End | 2001 |
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Causality; Coronary Disease; Coronary Thrombosis; End | 2001 |
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Causality; Coronary Disease; Coronary Thrombosis; End | 2001 |
[Anticoagulant or antiplatelet aggregation treatment after aortocoronary bypass].
Topics: Anticoagulants; Aspirin; Coronary Artery Bypass; Dipyridamole; Graft Occlusion, Vascular; Humans; Me | 1991 |
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical | 1986 |
50 trials available for ticlopidine and Graft Occlusion, Vascular
| Article | Year |
|---|---|
Does high-density lipoprotein influence the development of saphenous vein graft disease after coronary bypass surgery?: exploratory analysis from the CASCADE trial.
Topics: Aged; Angiography; Clopidogrel; Coronary Artery Bypass; Female; Follow-Up Studies; Graft Occlusion, | 2013 |
Correlates of saphenous vein graft hyperplasia and occlusion 1 year after coronary artery bypass grafting: analysis from the CASCADE randomized trial.
Topics: Aged; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Female; Follow-Up Studies; Graft Occ | 2013 |
Correlates of saphenous vein graft hyperplasia and occlusion 1 year after coronary artery bypass grafting: analysis from the CASCADE randomized trial.
Topics: Aged; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Female; Follow-Up Studies; Graft Occ | 2013 |
Correlates of saphenous vein graft hyperplasia and occlusion 1 year after coronary artery bypass grafting: analysis from the CASCADE randomized trial.
Topics: Aged; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Female; Follow-Up Studies; Graft Occ | 2013 |
Correlates of saphenous vein graft hyperplasia and occlusion 1 year after coronary artery bypass grafting: analysis from the CASCADE randomized trial.
Topics: Aged; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Female; Follow-Up Studies; Graft Occ | 2013 |
Effect of clopidogrel use post coronary artery bypass surgery on graft patency.
Topics: Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary | 2014 |
Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type.
Topics: Aspirin; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Thrombosis; Drug-Elutin | 2014 |
The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dose-Response Relationship, Drug; Double-Blin | 2014 |
Saphenous vein graft failure after coronary artery bypass surgery: insights from PREVENT IV.
Topics: Aged; Clopidogrel; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Female; Gra | 2014 |
ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting.
Topics: Aged; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug- | 2015 |
The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Female; Femora | 2016 |
Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial.
Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Coronary Vessels; Drug Therapy, Combination; Elect | 2016 |
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular | 2016 |
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; D | 2016 |
The role of clopidogrel and acetylsalicylic acid in the prevention of early-phase graft occlusion due to reactive thrombocytosis after coronary artery bypass operation.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Female; Graft Occlusion, Vascular; Humans; Male; Middl | 2008 |
Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disease; Drug Resista | 2008 |
Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis.
Topics: Acute Disease; Aged; Angina Pectoris; Blood Platelets; Clopidogrel; Coronary Angiography; Coronary T | 2009 |
Temporal relation between Clopidogrel cessation and stent thrombosis after drug-eluting stent implantation.
Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Female; | 2009 |
Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial.
Topics: Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Double-Blind Method; Drug-Eluti | 2009 |
Clopidogrel and aspirin versus clopidogrel alone on graft patency after coronary artery bypass grafting.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary Stenosis; Dose-Re | 2009 |
Randomized controlled trial of aspirin and clopidogrel versus aspirin and placebo on markers of smooth muscle proliferation before and after peripheral angioplasty.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Aspirin; Biomarkers; Blotting, Western; Cell P | 2009 |
Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials).
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Clopidogrel; Coronary Restenosis; Diabete | 2010 |
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis | 2010 |
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis | 2010 |
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis | 2010 |
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.
Topics: Aged; Amputation, Surgical; Aspirin; Australia; Blood Vessel Prosthesis Implantation; Chi-Square Dis | 2010 |
Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, randomized, controlled trial.
Topics: Administration, Oral; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Coronary A | 2010 |
Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Double-Blind Method; Femal | 2010 |
High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combinati | 2011 |
Combination therapy with warfarin plus clopidogrel improves outcomes in femoropopliteal bypass surgery patients.
Topics: Administration, Oral; Aged; Aspirin; Cardiovascular Diseases; Chi-Square Distribution; Clopidogrel; | 2012 |
Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY).
Topics: Aged; Clopidogrel; Coronary Restenosis; Coronary Vessels; Drug Administration Schedule; Drug Therapy | 2013 |
Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing gamma-radiation therapy for in-stent restenosis: Washington Radiation for In-Stent restenosis Trial (WRIST) 12 versus WRIST PLUS.
Topics: Aspirin; Brachytherapy; Clopidogrel; Coronary Restenosis; Drug Administration Schedule; Female; Gamm | 2002 |
Effect of antioxidant probucol for preventing stent restenosis.
Topics: Aged; Antioxidants; Aspirin; Blood Vessel Prosthesis Implantation; Coronary Angiography; Coronary Ar | 2002 |
Sustained platelet activation following intracoronary beta irradiation.
Topics: Angioplasty, Balloon, Coronary; Beta Particles; Blood Platelets; Brachytherapy; CD40 Ligand; Clopido | 2002 |
A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents.
Topics: Aged; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Artery Disease; Drug Ther | 2003 |
Combination antiplatelet therapy in patients with peripheral vascular bypass grafts.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Drug T | 2004 |
Randomized comparison of cilostazol vs ticlopidine for antiplatelet therapy after coronary stenting.
Topics: Aged; Cilostazol; Coronary Disease; Double-Blind Method; Female; Graft Occlusion, Vascular; Humans; | 2005 |
Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Vessel Prosthesis; Cerebrovascular Disorders; Clopidogrel; C | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Clopidogrel; Double-Blind Method; Female; Graft Occlusio | 2008 |
Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. Etude de la Ticlopidine après Pontage Fémoro-Poplité and the Association Universitaire de Recherche en Chirurgie.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Double-Blind Method; Female; Graft Occlusion, Vasc | 1997 |
Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Blood Vessel Prosthesis Implantation; Double-Blind Metho | 1998 |
PTCA of degenerated vein grafts: experience of two periods (1992-93 and 1996-97) in 780 patients.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis; Coronary Artery Bypass; Coro | 1998 |
Platelet aggregation and platelet-derived growth factor inhibition for prevention of insufficiency of the transjugular intrahepatic portosystemic shunt: a randomized study comparing trapidil plus ticlopidine with heparin treatment.
Topics: Drug Therapy, Combination; Female; Fibrinolytic Agents; Follow-Up Studies; Graft Occlusion, Vascular | 1999 |
beta-Particle-emitting radioactive stent implantation. A safety and feasibility study.
Topics: Adult; Aged; Aspirin; Beta Particles; Brachytherapy; Coronary Angiography; Coronary Disease; Feasibi | 1999 |
Usefulness of cilostazol versus ticlopidine in coronary artery stenting.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Cilostazol; Coronary Angiograp | 1999 |
Plasma levels of C-reactive protein after coronary stent implantation.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biomarkers; C-Reactive Protein; Coronary An | 2000 |
A randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. ISAR-SMART Study Investigators. Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Chemotherapy, Adju | 2000 |
Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial: Polish-American Local Lovenox NIR Assessment study (The POLONIA study).
Topics: Anticoagulants; Aspirin; Drug Administration Routes; Drug Delivery Systems; Enoxaparin; Female; Foll | 2001 |
Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin after coronary stent implantation: 1 and 6-month follow-up.
Topics: Aged; Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Stenosis; Drug Therapy, C | 2001 |
[Anticoagulant or antiplatelet aggregation treatment after aortocoronary bypass].
Topics: Anticoagulants; Aspirin; Coronary Artery Bypass; Dipyridamole; Graft Occlusion, Vascular; Humans; Me | 1991 |
Prevention of aorta-coronary bypass graft occlusion. Beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts: a double-blind study.
Topics: Angiography; Clinical Trials as Topic; Coronary Artery Bypass; Double-Blind Method; Electrocardiogra | 1987 |
Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis.
Topics: Anticoagulants; Aspirin; Blood Platelets; Blood Vessel Prosthesis; Cardiovascular Diseases; Clinical | 1986 |
Evaluation of antiplatelet agents in the prevention of aorto-coronary bypass occlusion.
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary A | 1986 |
Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis.
Topics: Anticoagulants; Arteriovenous Shunt, Surgical; Clinical Trials as Topic; Double-Blind Method; Graft | 1985 |
Platelet inhibitors versus anticoagulants for prevention of aorto-coronary bypass graft occlusion.
Topics: Acenocoumarol; Anticoagulants; Clinical Trials as Topic; Coronary Angiography; Coronary Artery Bypas | 1985 |
Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis.
Topics: Adult; Aged; Anticoagulants; Arteriovenous Shunt, Surgical; Clinical Trials as Topic; Double-Blind M | 1985 |
101 other studies available for ticlopidine and Graft Occlusion, Vascular
| Article | Year |
|---|---|
Contemporary Trends and Outcomes Associated With the Preprocedural Use of Oral P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
Topics: Adenosine; Aged; Blue Cross Blue Shield Insurance Plans; Clopidogrel; Drug Utilization Review; Ethni | 2017 |
Preventing graft restenosis after coronary artery bypass grafting with tissue-type plasminogen activator.
Topics: Aged; Aspirin; Blood Coagulation; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Female; | 2017 |
Quantifying Ischemic Risk After Percutaneous Coronary Intervention Attributable to High Platelet Reactivity on Clopidogrel (From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents Study).
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combi | 2017 |
High risk of stent thrombosis in the first 6 months after coronary stenting: Do not discontinue clopidogrel early after ACS.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Administration Schedule; Female; Graft Occlusion, V | 2017 |
Impact of Double Loading Regimen of Clopidogrel on Final Angiographic Results, Incidence of Upper Gastrointestinal Bleeding and Clinical Outcomes in Patients with STEMI Undergoing Primary Coronary Intervention.
Topics: Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gast | 2017 |
Five years on dual-antiplatelet therapy. DES thrombosis after clopidogrel withdrawal.
Topics: Aged; Antineoplastic Agents, Phytogenic; Clopidogrel; Drug-Eluting Stents; Follow-Up Studies; Graft | 2013 |
Impact of early versus late clopidogrel discontinuation on stent thrombosis following percutaneous coronary intervention with first- and second-generation drug-eluting stents.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Combined Modal | 2014 |
Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease.
Topics: Aged; Alleles; Angiography, Digital Subtraction; Ankle Brachial Index; Arteriosclerosis Obliterans; | 2014 |
An atypical presentation of an extremely late stent thrombosis after more than 7 years (2634 days) of DES implantation in a patient without obvious risk factors on regular dual antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Therapy, Combination; Drug-Elu | 2014 |
Clopidogrel after surgical coronary revascularization increases venous graft patency.
Topics: Coronary Artery Bypass; Coronary Disease; Female; Graft Occlusion, Vascular; Humans; Male; Platelet | 2014 |
Relationship between hyporesponsiveness to clopidogrel measured by thrombelastography and in stent restenosis in patients undergoing percutaneous coronary intervention.
Topics: Clopidogrel; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Percutaneous Coronary Int | 2014 |
Very late bioresorbable vascular scaffold thrombosis following discontinuation of antiplatelet therapy.
Topics: Absorbable Implants; Adenosine; Adult; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Graft Occlusio | 2015 |
Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; | 2014 |
Angiographic and clinical results of everolimus-eluting stent utilization in saphenous vein graft lesions (ARES).
Topics: Aged; Aged, 80 and over; Angiography; Angioplasty, Balloon; Aspirin; Clopidogrel; Coronary Artery By | 2015 |
A case of repetitive and simultaneous stent thromboses.
Topics: Coronary Angiography; Coronary Thrombosis; Diagnosis, Differential; Electrocardiography; Graft Occlu | 2015 |
Effectiveness of prolonged clopidogrel-based dual antiplatelet therapy after drug-eluting stent implantation: Evidence-based meta-analysis.
Topics: Aged; Aspirin; Clopidogrel; Coronary Restenosis; Drug Administration Schedule; Drug Combinations; Dr | 2015 |
Prognostic impact of high residual platelet reactivity after chronic total occlusion percutaneous coronary intervention in patients with diabetes mellitus.
Topics: Aged; Blood Platelets; Chronic Disease; Clopidogrel; Coronary Occlusion; Diabetes Mellitus; Dose-Res | 2015 |
Duration of dual antiplatelet therapy after coronary stenting.
Topics: Aspirin; Coronary Artery Disease; Drug Therapy, Combination; Graft Occlusion, Vascular; Humans; Plat | 2016 |
A case of subacute stent thrombosis after drug-coated balloon coronary angioplasty for in-stent restenosis under single anti-platelet therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Restenosis; Coronary Vessels; D | 2017 |
High platelet reactivity affects the clinical outcomes of patients undergoing percutaneous coronary intervention.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; F | 2016 |
Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Diabetes Mellitus; Female; Follow-Up Studies; Graft Occl | 2016 |
Aspirin resistance an underestimated risk in patients with drug-eluting stents?
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Drug-Eluting Stents; Graft Occlusion | 2008 |
Effect of clopidogrel on arteriovenous fistulas for dialysis.
Topics: Arteriovenous Shunt, Surgical; Clopidogrel; Graft Occlusion, Vascular; Humans; Platelet Aggregation | 2008 |
Effect of clopidogrel on arteriovenous fistulas for dialysis.
Topics: Arteriovenous Shunt, Surgical; Clopidogrel; Graft Occlusion, Vascular; Humans; Platelet Aggregation | 2008 |
Effect of clopidogrel on arteriovenous fistulas for dialysis.
Topics: Arteriovenous Shunt, Surgical; Clopidogrel; Graft Occlusion, Vascular; Humans; Platelet Aggregation | 2008 |
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Disease; | 2009 |
Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Thromb | 2009 |
Prolonged dual antiplatelet therapy improves clinical outcomes in high-risk patients implanted with sirolimus-eluting stents.
Topics: Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; | 2009 |
The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents.
Topics: Aged; Clopidogrel; Coronary Stenosis; Drug Administration Schedule; Drug-Eluting Stents; Female; Fol | 2009 |
A very late stent thrombosis in a patient with diabetes: a call for lifelong dual anti-platelet therapy.
Topics: Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Follow-Up Studies; Graft Occlusio | 2009 |
Invited commentary.
Topics: Aspirin; Clopidogrel; Coronary Artery Bypass; Female; Graft Occlusion, Vascular; Graft Survival; Hum | 2009 |
Obesity and cardiovascular thrombotic events in patients undergoing percutaneous coronary intervention with drug-eluting stents.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis; Body Mass Index; Clopidogrel; Coro | 2009 |
Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period.
Topics: Aged; Blood Vessel Prosthesis; Clopidogrel; Coronary Angiography; Drug-Eluting Stents; Female; Graft | 2009 |
Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis.
Topics: Aged; Aspirin; Case-Control Studies; Clopidogrel; Cohort Studies; Coronary Thrombosis; Drug Resistan | 2009 |
Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions.
Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disea | 2010 |
Platelet aggregation in intracranial stents may mimic in-stent restenosis.
Topics: Cerebral Angiography; Clopidogrel; Diagnosis, Differential; Drug Resistance; Graft Occlusion, Vascul | 2010 |
Stent thrombosis: who's guilty?
Topics: Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Blood Vessel Prosthesis; Cardiology; | 2009 |
Reduced intimal hyperplasia in rabbits via medical therapy after carotid venous bypass.
Topics: Administration, Oral; Animals; Atorvastatin; Benzopyrans; Calcium Dobesilate; Cardiovascular Agents; | 2009 |
Perioperative management of the patient with a coronary stent.
Topics: Algorithms; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Drug-Eluting Stent | 2010 |
Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period.
Topics: Blood Vessel Prosthesis; Clopidogrel; Drug-Eluting Stents; Graft Occlusion, Vascular; Humans; Platel | 2010 |
CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Vessel Prosthesi | 2010 |
Genetic variability in response to clopidogrel therapy: clinical implications.
Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2 | 2010 |
Clinical and angiographic outcomes with sirolimus-eluting stent for coronary bifurcation lesions. The J-PMS study.
Topics: Angioplasty; Aspirin; Calcinosis; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Coro | 2011 |
No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin | 2011 |
Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the preoperative aspirin and postoperative antiplatelets in coronary artery bypass grafting surgery.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Drug Therapy, Combination; Graft | 2011 |
Regarding "results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial".
Topics: Aspirin; Blood Vessel Prosthesis Implantation; Clopidogrel; Drug Therapy, Combination; Graft Occlusi | 2011 |
Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Graft Occlusion, Vascular; Hemor | 2011 |
Letter by Gasparovic et al regarding article, "Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) trial".
Topics: Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Artery Disease; Dr | 2011 |
Letter by Bisdas et al regarding article, "Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) trial".
Topics: Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary | 2011 |
Occlusion of modified Blalock-Taussig shunt after clopidogrel cessation.
Topics: Anticoagulants; Aspirin; Blalock-Taussig Procedure; Clopidogrel; Fatal Outcome; Graft Occlusion, Vas | 2012 |
Short thromboelastography and the identification of high platelet reactivity while on and off therapy.
Topics: Clopidogrel; Coronary Thrombosis; Drug Resistance; Female; Graft Occlusion, Vascular; Humans; Male; | 2012 |
Personalised antiplatelet therapy in stent thrombosis: observations from the Clopidogrel Resistance in Stent Thrombosis (CREST) registry.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Dose-Response Relationship, Drug; Drug Resistance; | 2012 |
Utility of VasoCT in the treatment of intracranial aneurysm with flow-diverter stents.
Topics: Adult; Aged; Angiography, Digital Subtraction; Angioplasty, Balloon; Aspirin; Catheterization; Cereb | 2012 |
Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention.
Topics: Aged; Amlodipine; Angioplasty, Balloon, Coronary; Clopidogrel; Cytochrome P-450 CYP3A; Drug Interact | 2012 |
Clopidogrel discontinuation after myocardial infarction and risk of thrombosis: a nationwide cohort study.
Topics: Adult; Aged; Clopidogrel; Denmark; Drug Administration Schedule; Epidemiologic Methods; Female; Graf | 2012 |
The use of the X-Sizer transluminal extraction catheter as an adjunct to stenting of occluded saphenous vein grafts.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Aspirin; Blood Vessel Prosthesis Implantation; Catheters, I | 2003 |
Atorvastatin and the ability of clopidogrel to inhibit platelet aggregation.
Topics: Atorvastatin; Clopidogrel; Dose-Response Relationship, Drug; Graft Occlusion, Vascular; Heptanoic Ac | 2003 |
Beta brachytherapy of an old degenerated saphenous vein graft with occlusive in-stent restenosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Beta Particles; Blood Vessel Prosthesis; Brachytherap | 2003 |
Resistance to antiplatelet drugs: is it real or relevant?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis Implantation; Brachytherapy; Clopid | 2004 |
Late stent thrombosis (> 1 year) following clopidogrel withdrawal after brachytherapy treatment: need to assess aspirin resistance?
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis Implantation; Brachytherapy; | 2004 |
[Cardiovascular pharmacology].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Fatty Acids, Omega-3; Fibrinolytic Agents; Graft Occl | 2004 |
Endovascular treatment of popliteal artery aneurysms: results of a prospective cohort study.
Topics: Aged; Aged, 80 and over; Aneurysm; Angioplasty; Blood Vessel Prosthesis Implantation; Clopidogrel; F | 2005 |
Stent thrombosis in patients treated with thienopyridines: clinical description of 10 cases.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Female; Follow- | 2004 |
Management and prevention of thrombotic stent occlusion.
Topics: Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis; Clopidogrel; Emergency Treatment; Graft Occ | 2005 |
Feasibility trial of carotid stenting with and without an embolus protection device.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Vessel Prosthesis Implantation; Carotid Artery, Commo | 2005 |
Idiopathic spontaneous coronary artery dissection and drug-eluting stents.
Topics: Adult; Aortic Dissection; Aspirin; Clopidogrel; Coronary Aneurysm; Coronary Angiography; Female; Gra | 2006 |
Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Clopidogrel; Drug Therapy, Combination; Graft Occlusion, Vas | 2005 |
Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Clopidogrel; Drug Therapy, Combination; Graft Occlusion, Vas | 2005 |
Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Clopidogrel; Drug Therapy, Combination; Graft Occlusion, Vas | 2005 |
Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Clopidogrel; Drug Therapy, Combination; Graft Occlusion, Vas | 2005 |
Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents.
Topics: Aged; Angiography; Case-Control Studies; Clopidogrel; Drug Delivery Systems; Female; Follow-Up Studi | 2006 |
Images in cardiology. Unexpected response of saphenous vein graft occlusion to antiplatelet drugs.
Topics: Aged; Aspirin; Clopidogrel; Graft Occlusion, Vascular; Humans; Male; Platelet Aggregation Inhibitors | 2006 |
Effect of clopidogrel on midterm graft patency following off-pump coronary revascularization surgery.
Topics: Clopidogrel; Cohort Studies; Coronary Artery Bypass, Off-Pump; Female; Graft Occlusion, Vascular; Gr | 2006 |
What is the optimal management for preventing saphenous vein graft diseases?: early results of intravascular angioscopic assessment.
Topics: Aged; Aged, 80 and over; Angioscopy; Anticoagulants; Aspirin; Coronary Artery Bypass; Graft Occlusio | 2007 |
Factitious anticoagulant-resistance as a cause of recurrent arterial bypass graft occlusions.
Topics: Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Drug Resistance; Drug Therapy, Co | 2007 |
Drug interaction with anti-mycobacterial treatment as a cause of clopidogrel resistance.
Topics: Abciximab; Aged; Antibiotics, Antitubercular; Antibodies, Monoclonal; Clopidogrel; Drug Interactions | 2008 |
Randomized trials in hemodialysis patients: time to step up to the plate.
Topics: Arteriovenous Shunt, Surgical; Clopidogrel; Graft Occlusion, Vascular; Humans; Platelet Aggregation | 2008 |
[Results in peripheral arterial revascularization with the use of various antiaggregating substances].
Topics: Adult; Aged; Anticoagulants; Blood Vessel Prosthesis; Dicumarol; Graft Occlusion, Vascular; Humans; | 1984 |
Pharmacological prophylaxis against postoperative graft occlusion after peripheral vascular surgery: a world-wide survey.
Topics: Anticoagulants; Aspirin; Data Collection; Dipyridamole; Drug Utilization; Graft Occlusion, Vascular; | 1995 |
[Stent after-care: new approaches to coagulation inhibiting therapy].
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Blood Coagulation Tests; Coronary Disease; | 1995 |
The antithrombotic effects of ticlopidine and aspirin in a microvascular thrombogenic model.
Topics: Administration, Oral; Animals; Aspirin; Femoral Artery; Graft Occlusion, Vascular; Male; Microsurger | 1995 |
[Pilot study of the efficacy of ticlopidine in early patency of coronary endoprostheses].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coronary Disease; Coron | 1994 |
[An experimental study of arterial graft implantation--the effects of an anti-thrombin agent, argatroban, and an anti-platelet agent, clopidogrel (SR 25990 C) on the inner capsule].
Topics: Angioscopy; Animals; Antithrombins; Aorta, Abdominal; Arginine; Blood Coagulation; Blood Vessel Pros | 1994 |
Pharmacological control of intimal hyperplasia in small diameter polytetrafluoroethylene grafts. An experimental study.
Topics: Animals; Blood Vessel Prosthesis; Carotid Arteries; Carotid Artery Thrombosis; Endothelium, Vascular | 1996 |
Antiplatelet therapy and patency of saphenous-vein bypass grafts in the legs.
Topics: Aspirin; Graft Occlusion, Vascular; Humans; Multicenter Studies as Topic; Platelet Aggregation Inhib | 1998 |
Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis.
Topics: Animals; Arteriovenous Shunt, Surgical; Aspirin; Bleeding Time; Blood Platelets; Clopidogrel; Corona | 1998 |
Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts.
Topics: Anticoagulants; Aspirin; Coronary Artery Bypass; Dipyridamole; Fibrinolytic Agents; Graft Occlusion, | 1998 |
Elective Wiktor GX stenting for symptomatic stenosis in old aortocoronary saphenous vein bypass grafts: the Antwerp experience.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Artery Bypass; Female; Graft Occlusion, Vascular; Hum | 1999 |
Saphenous vein graft disease treated with the Wiktor Hepamed stent: procedural outcome, in-hospital complications and six-month angiographic follow-up.
Topics: Aged; Aspirin; Coronary Angiography; Coronary Artery Bypass; Female; Fibrinolytic Agents; Follow-Up | 2000 |
Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine.
Topics: Abciximab; Adult; Aged; Antibodies, Monoclonal; Blood Vessel Prosthesis Implantation; Cardiac Cathet | 2000 |
Risk of neutropenia with clopidogrel.
Topics: Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Disease; Graft Occlusion, Vascular; Huma | 2000 |
Efficacy of heparin-coated stent in early setting of acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coated Materials, Biocompatible; Cor | 2001 |
Short-term outcome of stent implantation in saphenous vein grafts: predictors of distal embolization and restenosis.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Combined Modality Therapy; Comorbidity; Coronary Ang | 2001 |
Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibod | 2001 |
Bench to bedside: the development of rapamycin and its application to stent restenosis.
Topics: Angioplasty, Balloon, Coronary; Animals; Calcineurin Inhibitors; Carrier Proteins; Cell Cycle Protei | 2001 |
Prevention of venous graft sclerosis with clopidogrel and aspirin combined with a mesh tubing in a dog model of arteriovenous bypass grafting.
Topics: Animals; Aspirin; Blood Vessel Prosthesis; Carotid Artery, Common; Clopidogrel; Dogs; Drug Therapy, | 2001 |
Aspirin versus clopidogrel for synthetic graft patency after peripheral arterial bypass grafting.
Topics: Arteries; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Graft Occlusion, Vascular; Humans; Male; Pe | 2001 |
Blood compatibility of venous prosthesis made of textile or non-textile material.
Topics: Animals; Biocompatible Materials; Blood Vessel Prosthesis; Endothelium, Vascular; Erythrocytes; Fibr | 1992 |
[Arterioarterial shunt coated with collagen. A model of acute arterial thrombosis for testing antithrombotic agents in rats].
Topics: Animals; Aspirin; Carotid Arteries; Clopidogrel; Collagen; Disease Models, Animal; Fistula; Graft Oc | 1991 |
The pathogenesis of thrombosis in venous prostheses.
Topics: Animals; Blood Vessel Prosthesis; Graft Occlusion, Vascular; Male; Microscopy, Electron, Scanning; P | 1990 |
[Role of platelet anti-aggregants in cardiovascular surgery].
Topics: Aspirin; Coronary Artery Bypass; Dipyridamole; Graft Occlusion, Vascular; Humans; Platelet Aggregati | 1987 |
Microcirculatory changes during skin allograft rejection and prolongation of survival time by antiplatelet agents.
Topics: Acrylates; Animals; Arterioles; Azathioprine; Blood Platelets; Capillaries; Graft Occlusion, Vascula | 1986 |
[Mode of action and clinical evaluation of platelet aggregation inhibitors].
Topics: Aspirin; Cerebrovascular Disorders; Dipyridamole; Graft Occlusion, Vascular; Humans; Ketanserin; Myo | 1987 |
Ticlopidine versus aspirin and dipyridamole: influence on platelet deposition and three-month patency of polytetrafluoroethylene grafts.
Topics: Animals; Anticoagulants; Aspirin; Blood Vessel Prosthesis; Dipyridamole; Dogs; Female; Femoral Arter | 1986 |